Related Experiment Videos
[Resistance to anticancer drugs in relation to cytochrome P-450]
T Kamataki1, M Kitada, M Komori
1Division of Analytical Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University.
Abstract:
Cytochrome p-450 is a product of a multigene family, and catalyzes the activation and the detoxication of a wide variety of exogenous as well as endogenous compounds. Recent studies have the purified forms of cytochrome p-450 and provided evidence that some anticancer agents are metabolically activated by the cytochrome. In general, cancer cells express lower amounts of cytochrome p-450 as compared to normal liver cells. We recently succeeded in purifying P-450 HFLa, a form of cytochrome P-450 in human fetal livers. Examinations using antibodies to P-450 HFLa, however, showed that proteins cross-reactive with antibodies to P-450 HFLa existed in gynecologic malignancies. Development of multiple drug resistance is usually associated with a decrease in the content of cytochrome P-450, which is in contrast with glutathione S-transferase and a few other enzymes. The mechanisms responsible for such altered enzyme activity by multiple drug resistance are unclear as yet.
Insights
Cytochrome P-450 (CYP450) enzymes activate anticancer drugs but are often decreased in cancer cells. This study identified a fetal liver CYP450 form (P-450 HFLa) present in gynecologic cancers, suggesting a novel role in drug resistance.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Context:
- Cytochrome P-450 (CYP450) enzymes are crucial for metabolizing diverse compounds.
- Recent research indicates CYP450 involvement in the metabolic activation of anticancer agents.
- Cancer cells generally exhibit lower CYP450 expression compared to normal liver cells.
Purpose:
- To investigate the presence and potential role of a specific cytochrome P-450 form, P-450 HFLa, in gynecologic malignancies.
- To explore the relationship between CYP450 expression and multiple drug resistance in cancer.
Summary:
- Cytochrome P-450 (CYP450) is a multigene family involved in compound metabolism.
- Purified CYP450 forms activate anticancer drugs, yet cancer cells often have reduced CYP450 levels.
- This study identified P-450 HFLa in human fetal livers and detected cross-reactive proteins in gynecologic malignancies, contrasting with typical drug resistance mechanisms.
Impact:
- Identifies P-450 HFLa as a potential biomarker or therapeutic target in gynecologic cancers.
- Highlights the complex and potentially paradoxical role of CYP450 in cancer drug resistance.
- Suggests further research into the mechanisms underlying altered CYP450 activity in multidrug-resistant cancers.